Oct 04, 2018
Soligenix Announces Poster Presentations of its Ricin Vaccine and Dusquetide Oral Mucositis Programs at the 2018 NORD Rare Diseases and Orphan Products Breakthrough Summit
Sep 13, 2018
NIH selects Soligenix's SGX942 in the Treatment of Oral Mucositis for the Commercialization Accelerator Program
Sep 05, 2018
Soligenix to Present at BioCentury's 25th Annual NewsMakers in the Biotech Industry
Sep 04, 2018
Soligenix Announces Publication of Positive Long-Term Data Supporting Thermostability and Conformational Integrity of the RiVax® Ricin Toxin Vaccine
Aug 22, 2018
Soligenix Receives US Patent for Improved Production of Synthetic Hypericin
Aug 08, 2018
Soligenix Announces Recent Accomplishments And Second Quarter 2018 Financial Results
Jul 26, 2018
Soligenix Announces a RiVax® Program Presentation at the 31st Annual Congress on Vaccines, Clinical Trials & B2B in Vancouver, Canada
Jul 24, 2018
Soligenix Announces Appointment of Mark Pearson to its Board of Directors
Jul 19, 2018
Soligenix - Driving Towards Key Inflection Points with Two Pivotal Phase 3 Clinical Trials
Jul 09, 2018
Soligenix Receives European and Canadian Patents for its Ricin Toxin Vaccine (RiVax®) Formulation
Jul 02, 2018
Soligenix Announces Closing of $8,000,000 At The Market Public Offering
Jun 28, 2018
Soligenix, Inc. Prices $8,000,000 Public Offering At The Market
Jun 04, 2018
Soligenix Announces Poster at the 2018 American Society of Microbiology Microbe Conference in Atlanta, Georgia
May 11, 2018
Soligenix Announces Recent Accomplishments And First Quarter 2018 Financial Results
May 07, 2018
Soligenix to Present at the NYC Oncology Investor Conference 2018
Mar 22, 2018
Soligenix Receives Orphan Drug Designation from the European Commission for RiVax® for Prevention of Ricin Poisoning
Mar 15, 2018
Soligenix Announces Recent Accomplishments And Year-End 2017 Financial Results
Mar 13, 2018
Soligenix to Present at the 12th Annual International Partnering Conference Bio-Europe Spring
Jan 25, 2018
Soligenix - Driving Towards Key Inflection Points with Two Pivotal Phase 3 Clinical Trials
Jan 02, 2018
Soligenix Announces US Patent Issuance for Use of Dusquetide in Oral Mucositis